| 000 | 01536 a2200433 4500 | ||
|---|---|---|---|
| 005 | 20250517123452.0 | ||
| 264 | 0 | _c20171215 | |
| 008 | 201712s 0 0 eng d | ||
| 022 | _a1873-2518 | ||
| 024 | 7 |
_a10.1016/j.vaccine.2016.10.019 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aLuttjeboer, Jos | |
| 245 | 0 | 0 |
_aThreshold cost-effectiveness analysis for a therapeutic vaccine against HPV-16/18-positive cervical intraepithelial neoplasia in the Netherlands. _h[electronic resource] |
| 260 |
_bVaccine _c12 2016 |
||
| 300 |
_a6381-6387 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article | ||
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 | _aAged, 80 and over |
| 650 | 0 | 4 | _aCohort Studies |
| 650 | 0 | 4 | _aCost-Benefit Analysis |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 |
_aHuman papillomavirus 16 _xisolation & purification |
| 650 | 0 | 4 |
_aHuman papillomavirus 18 _xisolation & purification |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 | _aModels, Statistical |
| 650 | 0 | 4 |
_aNetherlands _xepidemiology |
| 650 | 0 | 4 |
_aPapillomavirus Infections _xeconomics |
| 650 | 0 | 4 |
_aPapillomavirus Vaccines _xadministration & dosage |
| 650 | 0 | 4 | _aQuality-Adjusted Life Years |
| 650 | 0 | 4 |
_aUterine Cervical Dysplasia _xeconomics |
| 700 | 1 | _aSetiawan, Didik | |
| 700 | 1 | _aCao, Qi | |
| 700 | 1 | _aCahh Daemen, Toos | |
| 700 | 1 | _aPostma, Maarten J | |
| 773 | 0 |
_tVaccine _gvol. 34 _gno. 50 _gp. 6381-6387 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1016/j.vaccine.2016.10.019 _zAvailable from publisher's website |
| 999 |
_c26579830 _d26579830 |
||